Novo Nordisk (NVO) Could Be 59% Undervalued On Its GLP 1 Growth Narrative

Novo Nordisk (NYSE:NVO) has rebranded as Novo, introduced the slogan “Lasting Health Starts Now,” and refreshed its internal culture under “The Novo Way,” ahead of a detailed strategy update at its 21 September Capital Markets Day.

Recent trading has been softer, with the share price at US$42.53 after falling 7.3% over the past month and the year-to-date share price return down 18.8%, while the 3-year total shareholder return has declined 51.7%. This suggests sentiment has cooled even as investors wait to see how Novo’s refreshed identity and upcoming Capital Markets Day reshape perceptions of its long-term potential and risk profile.

Compare Novo Nordisk’s recent pullback with other large, profitable healthcare names by scanning our hand-picked list of solid balance sheet and fundamentals (22 results), which is likely to handle market swings with fewer balance sheet surprises.

After a pullback this steep and a refreshed story built around “Lasting Health Starts Now,” does Novo Nordisk now offer enough upside to justify the risks that come with buying into the valuation here?

Most Popular Narrative: 59% Undervalued

The most followed narrative on Novo Nordisk pitches a fair value of $102.97 against the last close at $42.53, which sets up a wide gap that current pricing has not closed.

The GLP-1 market is growing at an unprecedented rate, with global sales projected to more than double from 2025 levels to reach $190 billion to $200 billion by 2035, with some forecasts projecting the market to exceed $250 billion by 2030-2034 due to the expansion into new therapeutic areas and rapid adoption of oral treatments.

See why 58 investors see Novo Nordisk as 59% undervalued.

Result: Fair Value of $102.97 (UNDERVALUED)

Still, the bullish Novo Nordisk story can fray quickly if projected GLP-1 adoption or adolescent approvals arrive slower than expected, or if acquisition hopes disappoint.

Find out about the key risks to this Novo Nordisk narrative.

Next Steps

Mixed sentiment on Novo Nordisk is clear, with both risks and rewards in play. Act quickly by weighing the 3 key rewards and 2 important warning signs.

Hunting For More Ideas Beyond Novo Nordisk?

If Novo Nordisk has sharpened your focus but you are not ready to stop at one opportunity, use the Simply Wall Street Screener to surface more targeted ideas.

• Target dependable income streams by reviewing 6 dividend fortresses that aim to combine higher yields with sturdier business profiles than many headline stocks.
• Zero in on quality at a discount by scanning the 34 high quality undervalued stocks that pair solid fundamentals with prices that screens classify as below estimated worth.
• Protect your downside first and upside second by filtering for 11 resilient stocks with low risk scores that feature stronger balance sheets and more measured risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com